Atara Biotherapeutics announced today its third‑quarter 2025 financial results, reporting a net loss of $4.303 million on revenue of $3.453 million. Operating expenses totaled $7.027 million, comprising $115 k in commercialization costs, $2.925 million in research and development, and $3.987 million in general and administrative expenses.
The company also confirmed that it has transferred the Biologics License Application (BLA) for its lead allogeneic T‑cell therapy, tab‑cel (Ebvallo), to Pierre Fabre Laboratories. In return, Atara will receive a $40 million milestone payment upon FDA approval of the tab‑cel BLA, with a Prescription Drug User Fee Act (PDUFA) target action date of January 10 2026.
The transfer of regulatory responsibilities to Pierre Fabre reduces Atara’s manufacturing and commercialization costs, while the company continues to support Pierre Fabre at its expense for certain regulatory activities. This shift is intended to conserve capital and accelerate the U.S. regulatory pathway for tab‑cel.
The combination of a modest earnings loss, a significant milestone payment contingent on regulatory approval, and a clear PDUFA timeline underscores the company’s focus on bringing tab‑cel to the U.S. market and highlights the financial and operational implications for investors moving forward.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.